Related Experiment Video
Updated: Feb 26, 2026

Quantitative PCR-based Assay to Measure Sonic Hedgehog Signaling in Cellular Model of Ciliogenesis
Published on: January 31, 2025
mTORC2 regulates hedgehog pathway activity by promoting stability to Gli2 protein and its nuclear translocation
Samarpan Maiti1, Susmita Mondal1, Eswara M Satyavarapu1
1Cancer Biology and Inflammatory Disorder Division, Council of Scientific and Industrial Research (CSIR)-Indian Institute of Chemical Biology, 4, Raja S.C. Mullick Road, Jadavpur, Kolkata 700032, India.
Abstract:
mTORC2 is aberrantly activated in cancer and therefore is considered to be an important therapeutic target. The hedgehog pathway, which is also often hyperactivated, regulates transcription of several genes associated with angiogenesis, metastasis, cellular proliferation and cancer stem cell (CSC) regeneration. However, the contribution of mTORC2 toward hedgehog pathway activity has not been explored yet. Here we have addressed the molecular cross talk between mTORC2 and hedgehog pathway activities in the context of glioblastoma multiforme, a malignant brain tumor using as a model system. We observed that higher mTORC2 activity enhanced the expression of a few hedgehog pathway molecules (Gli1, Gli2 and Ptch1) and amplified its target genes (Cyclin D1, Cyclin D2, Cyclin E, Snail, Slug and VEGF) both in mRNA and protein levels as corroborated by increased metastasis, angiogenesis, cellular proliferation and stem cell regeneration. Inhibition of mTORC2 formation decreased hedgehog pathway activity and attenuated all these above-mentioned events, suggesting their cross talk with each other. Further investigations revealed that mTORC2 inhibited ubiquitination of Gli2 by inactivating GSK3β, and thus it promotes stability to Gli2 and its nuclear translocation. Moreover, enhanced mTORC2 activity led to the increased clonogenic properties and CD133+ cells, indicating its role in CSC regeneration. mTORC2 inhibitor directed the reduction of hedgehog pathway proteins and also reduced CSCs. Thus, our observations support a role for elevated mTORC2 activity in regulating angiogenesis, metastasis, cellular proliferation and CSC regeneration via hedgehog pathway activity. Taken together, it provides a rationale for including the mTOR2 inhibitor as part of the therapeutic regimen for CSCs.
Insights
Mammalian target of rapamycin complex 2 (mTORC2) signaling enhances the hedgehog pathway, promoting glioblastoma growth, metastasis, and cancer stem cell regeneration. Inhibiting mTORC2 reduces these effects, suggesting mTORC2 as a therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Aberrant activation of mammalian target of rapamycin complex 2 (mTORC2) is implicated in cancer, making it a key therapeutic target.
- The hedgehog signaling pathway is frequently hyperactivated in cancer, regulating genes involved in angiogenesis, metastasis, proliferation, and cancer stem cell (CSC) regeneration.
Purpose of the Study:
- To investigate the molecular crosstalk between mTORC2 and the hedgehog pathway in glioblastoma multiforme.
- To determine the role of mTORC2 in regulating hedgehog pathway activity and its downstream effects on cancer progression and CSCs.
Main Methods:
- Utilized glioblastoma multiforme as a model system to study the interaction between mTORC2 and the hedgehog pathway.
- Assessed the expression of hedgehog pathway molecules (Gli1, Gli2, Ptch1) and target genes (Cyclin D1/D2/E, Snail, Slug, VEGF) at mRNA and protein levels.
- Investigated the effect of mTORC2 inhibition on hedgehog pathway activity, cancer cell proliferation, metastasis, angiogenesis, and CSC regeneration, including Gli2 ubiquitination and GSK3β activity.
Main Results:
- Elevated mTORC2 activity increased the expression of hedgehog pathway components and amplified its target genes, correlating with enhanced metastasis, angiogenesis, proliferation, and CSC regeneration.
- Inhibition of mTORC2 decreased hedgehog pathway activity and attenuated these cancer-promoting events, indicating a significant crosstalk.
- mTORC2 was found to inhibit Gli2 ubiquitination by inactivating GSK3β, thereby promoting Gli2 stability and nuclear translocation, leading to increased clonogenic properties and CD133+ cells.
Conclusions:
- Elevated mTORC2 activity drives angiogenesis, metastasis, cellular proliferation, and CSC regeneration through the hedgehog pathway in glioblastoma.
- mTORC2 inhibition effectively reduces hedgehog pathway proteins and CSCs, highlighting its therapeutic potential.
- These findings provide a strong rationale for incorporating mTORC2 inhibitors into therapeutic regimens for targeting CSCs in glioblastoma.
More Related Videos
10:16Primary Cell Cultures to Study the Regeneration Potential of Murine Müller Glia after MicroRNA Treatment
Published on: March 28, 2022
11:32Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
Published on: March 27, 2020
Related Concept Videos
Hedgehog Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
TGF - β Signaling Pathway
GTPases and their Regulation
GTPases and their Regulation
Large G-proteins,...